HCA Healthcare heads into the final stretch before its October 23 earnings with a notable divergence between recovering price momentum and a Street that has quietly ratcheted down its targets since the last print.
The stock gained 5.4% on the week to close at $423.82, clawing back most of July's post-earnings damage. That compares favorably to closest peer UHS, which added a more modest 2.9% over the same stretch, while THC managed less than 1%. The rebound follows Q2 results in late July that were well-received — the stock jumped 3.5% the next day and added a further 6.9% over the following week, its best short-term earnings reaction in recent memory.
Options positioning corroborates the improved tone. Call flow is outrunning puts — the put/call ratio has dropped to 0.68, below its 20-day average of 0.73 and at the more bullish end of the past year's range (52-week low is 0.58). The z-score of -0.70 isn't dramatic, but the direction is clear: options traders have shifted away from the defensive posture that dominated through mid-August, when the PCR ran above 0.84. The lending market adds nothing to the short thesis. Borrow availability is ample at over 1,000% — roughly ten shares available for every one currently borrowed — and cost to borrow, while up about 24% on the week, is still only 0.47%. Short interest itself is low at 2.7% of free float, drifting up around 8% over the past month but well inside any squeeze-relevant range. The borrow market is not the story here.
The Street tells a more complicated tale. Bulls have a genuine case: Goldman Sachs holds a Buy with a $485 target, Mizuho and Truist both see material upside from current levels, and the consensus mean target of $453 implies roughly 7% from here. But nearly every major house trimmed its target after July earnings — Goldman cut from $558 to $485, JPMorgan brought its Neutral target down from $490 to $425, Morgan Stanley (Underweight) took its target to $380. The pattern is consistent with analysts still expecting growth but revising down the pace of it. The most recent action, RBC reiterating Outperform at $435 on September 8, lands just above the current price and signals the cautious optimism is real but not generous. On valuation, HCA trades at roughly 13.6x trailing earnings and 9.0x EV/EBITDA — both near the low end of recent ranges, which the bull case frames as an entry point and the bear case reads as a reflection of structural pressure on margins.
The ownership picture carries one headline fact worth flagging. Thomas F. Frist Jr. filed a Schedule 13D in February declaring a 31.6% stake — an activist-flag disclosure, though in this case it reflects the founding family's long-standing position rather than an external agitator. That 13D sits on the register and is worth noting, even though no associated campaign has materialized. The standard caveat applies: the stake is as-last-disclosed around the 5% filing threshold, and positions can move without triggering a further filing. Separately, Wellington Management added close to 800,000 shares as of its last reported period, the most notable institutional accumulation in the top-fifteen holder list.
The bear case centers on the structural headwinds HCA's own guidance revision last quarter flagged — healthcare exchange mix shifts, tighter payor dynamics, and a labor cost environment that remains stubborn in urban markets. The factor scorecard reflects the tension: EV/EBIT ranks in the 79th percentile across the universe, a genuine valuation argument for bulls, but forward EPS momentum scores are weak (14th percentile for 12-month forward year-on-year growth), and the short score of 41.8 has nudged up modestly this week without signaling any conviction from either side. The October 23 print is therefore less about whether HCA can grow and more about whether management's updated volume and margin guidance is enough to close the gap between the current price and a Street consensus that already carries significant skepticism baked in.
See the live data behind this article on ORTEX.
Open HCA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
